NUMINUS WELLNESS INC - NUMIF STOCK NEWS

Numinus Wellness has announced its Cedar Clinical Research (CCR) site has been selected for Cybin's Phase 3 clinical trial of CYB003 for Major Depressive Disorder (MDD). The trial, set to begin enrollment mid-2024, follows promising Phase 2 results where 75% of participants achieved remission from depression symptoms. The U.S. FDA has granted breakthrough therapy designation for CYB003. The Murray, Utah location is among the 15 U.S. sites chosen for the study. Dr. Paul Thielking will lead the trial as Principal Investigator. This partnership aims to advance psychedelic-assisted therapy and address unmet needs in mental health care.

Numinus Wellness (TSX: NUMI, OTCQX: NUMIF), a mental health care company focused on psychedelic-assisted therapies, has received Health Canada approval for a new study. The trial will explore the feasibility of a group model for MDMA-assisted psychotherapy, aiming to determine the optimal number of therapists needed for group sessions. The study will involve trainee practitioners who will gain core competencies by observing seasoned therapists and experiencing MDMA in a therapeutic setting. This research aims to enhance the understanding of administering MDMA for severe mental disorders like PTSD.

Numinus Wellness Inc. announces a strategic plan to focus on U.S. operations for higher growth and profitability. The company is enhancing its wellness clinics and clinical research facilities, launching a membership program for healthcare professionals in psychedelic-assisted therapies, and collaborating with Field Trip Health. Numinus also entered into an agreement with Field Trip Health to transition Canadian clinic operations, aiming to optimize therapy and training expertise while maximizing shareholder returns.

Numinus Wellness Inc. announces Cedar Clinical Research as a site for Cybin's Phase 3 trial of CYB003 for Major Depressive Disorder. In Phase 2, 75% of patients achieved remission from depression symptoms. The FDA granted CYB003 breakthrough therapy designation. Phase 3 enrollment starts mid-2024.

Numinus Wellness Inc. provides a corporate update focusing on streamlining operations, maximizing shareholder returns, expanding Psychedelic Assisted Therapy training, and exploring opportunities to redefine, divest, or discontinue Canadian clinical operations. The company sharpens its focus on growth opportunities in the U.S. while maintaining support for Canadian organizations and healthcare professionals.

Numinus Wellness Inc. reported Q2 Fiscal 2024 results with a cash position of $6.6 million, a gross profit of $0.5 million, and revenue of $5.0 million. The company doubled enrolment in training programs, managed 15 clinical trials, and provided 17,661 client appointments. Numinus submitted a Clinical Trial Application to Health Canada for MDMA-assisted psychotherapy. Despite revenue and gross margin declines, the company focused on profitability and cost containment measures. Operational highlights include revenue decline in wellness clinics, clinical research revenues, and clinical training program success. Corporate updates included key appointments and retirements. Numinus ended the quarter with $6.6 million in cash and a positive outlook for growth in the psychedelic sector.

Numinus Wellness Inc. to release financial results for Q2 2024 on April 15, 2024. The company focuses on psychedelic-assisted therapies for mental health care.

Numinus Wellness Inc. submits a Clinical Trial Application to Health Canada for a group model in MDMA-assisted psychotherapy, focusing on practitioner training and safety.

Numinus Wellness Inc. announces the new date for its Annual General Meeting, along with the appointment of directors and an interim Chief Financial Officer. The company is focused on mental health care and innovative behavioral health treatments, with a strong emphasis on evidence-based therapies.